The DOI matches its Crossref record, with a small difference in title or year; 150 of the 150 references it cites were found in a registry or an index.
Rapid Onset of Antidepressant Action: A New Paradigm in the Research and Treatment of Major Depressive Disorder
Open accessAbstract
OBJECTIVE: Current therapeutics of depression are similar in their time to antidepressant action and often take weeks to months to achieve response and remission, which commonly results in considerable morbidity and disruption in personal, professional, family, and social life, as well as risk for suicidal behavior. Thus, treatment strategies presenting a rapid improvement of depressive symptoms--within hours or even a few days--and whose effects are sustained would have an enormous impact on public health. This article reviews the published data related to different aspects of rapid improvement of depressive symptoms. DATA SOURCES: Literature for this review was obtained through a search of the MEDLINE database (1966-2007) using the following keywords and phrases: rapid response, antidepressant, time to, glutamate, sleep, therapeutics, latency, and depression. The data obtained were organized according to the following topics: clinical relevance and time course of antidepressant action, interventions showing evidence of rapid response and its potential neurobiological basis, and new technologies for better understanding rapid anti-depressant actions. DATA SYNTHESIS: A limited number of prospective studies evaluating rapid antidepressant actions have been conducted. Currently, only a few interventions have been shown to produce antidepressant response in hours or a few days. The neurobiological basis of these rapid antidepressant actions is only now being deciphered. CONCLUSIONS: Certain experimental treatments can produce antidepressant response in a much shorter period of time than existing medications. Understanding the molecular basis of these experimental interventions is likely to lead to the development of improved therapeutics rather than simply furthering our knowledge of current standard antidepressants.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nonetheless, the definition as well the optimal method and time-frame to evaluate rapid antidepressant actions have varied across the literature, without clear consensus (1).”
From Total Sleep Deprivation Followed by Bright Light Therapy as Rapid Relief for Depression: A Pragmatic Randomized Controlled Trial (2021) · cites this paper as [1]
Citations
Cites
Bliss, T. V. P., & Gardner‐Medwin, A. R. (1973) · The Journal of Physiology · doi:10.1113/jphysiol.1973.sp010274 · Cited by 7,437
Deep Brain Stimulation for Treatment-Resistant Depression
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., Schwalb, J. M., & Kennedy, S. H. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.014 · Cited by 4,059
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationThe functioning and well-being of depressed patients. Results from the Medical Outcomes Study
Wells, K. B. (1989) · JAMA · doi:10.1001/jama.262.7.914 · Cited by 2,808
Sleep function and synaptic homeostasis
Tononi, G., & Cirelli, C. (2006) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2005.05.002 · Cited by 2,151
The Functioning and Well-being of Depressed Patients: Results From the Medical Outcomes Study
Wells, K. B. (1989) · JAMA · doi:10.1001/jama.1989.03430070062031 · Cited by 2,130
Hippocampal atrophy in recurrent major depression
Sheline, Y. I., Wang, P. W., Gado, M. H., Csernansky, J. G., & Vannier, M. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.3908 · Cited by 1,932
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression
Shirayama, Y., Chen, A. C.-H., Nakagawa, S., Russell, D. S., & Duman, R. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03251.2002 · Cited by 1,654
Cited by
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Self-citationZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
“Such limitations signifcantly contribute to the life disruptions experienced by individuals ith this disorder, and the delay in treating suicidal behavior is an ssue of particular concern in this already vulnerable population (5).”
BackgroundSelf-citationThe Forced Swim Test as a Model of Depressive-like Behavior
Yankelevitch-Yahav, R., Franko, M., Huly, A., & Doron, R. (2015) · Journal of Visualized Experiments · doi:10.3791/52587 · Cited by 754
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525
“While a number of therapies are available for treatment of major depression, a major limitation of all existing antidepressants is delayed onset of action (1).”
BackgroundSelf-citationBiological, Psychological, and Social Determinants of Depression: A Review of Recent Literature
Remes, O., Mendes, J. F., & Templeton, P. (2021) · Brain Sciences · doi:10.3390/brainsci11121633 · Cited by 482
Emerging role of glutamate in the pathophysiology of major depressive disorder
Hashimoto, K. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.005 · Cited by 381
Ibrahim, L., DiazGranados, N., Franco-Chaves, J., Brutsche, N., Henter, I. D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D. A., Manji, H. K., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.338 · Cited by 309
Self-citationMathew, S. J., Murrough, J. W., aan het Rot, M., Collins, K. A., Reich, D. L., & Charney, D. S. (2010) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000169 · Cited by 294
“Safe and effective therapies with rapid onset of action for treatment-resistant major depression (TRD) are needed (Machado-Viera et al. 2008).”
Zarate, C. A., Brutsche, N., Laje, G., Luckenbaugh, D. A., Venkata, S. L. V., Ramamoorthy, A., Moaddel, R., & Wainer, I. W. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.004 · Cited by 282
“Current antidepressants largely modulate the serotoergic and noradrenergic systems and usually take several weeks to xert an appreciable response (2).”
BackgroundSelf-citationCognitive Behavioural Therapy for Insomnia (CBT-I) to treat depression: a systematic review
Cunningham, J. E. A., & Shapiro, C. M. (2018) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2017.12.012 · Cited by 278
Ketamine and the next generation of antidepressants with a rapid onset of action
Machado-Vieira, R., Salvadore, G., DiazGranados, N., & Zarate, C. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.02.010 · Cited by 276
Self-citationEffect of Zuranolone vs Placebo in Postpartum Depression
Deligiannidis, K. M., Meltzer-Brody, S., Gunduz-Bruce, H., Doherty, J., Jonas, J., Li, S., Sankoh, A. J., Silber, C., Campbell, A. D., Werneburg, B., et al. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.1559 · Cited by 277
Wu, J. C., Kelsoe, J. R., Schachat, C., Bunney, B. G., DeModena, A., Golshan, S., Gillin, J. C., Potkin, S. G., & Bunney, W. E. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.02.018 · Cited by 263
“Conventional mediations typically require 2–8 weeks for response, prolonging uffering and suicidal risk (2,3).”
BackgroundZarate, C. A., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N. E., Smith, M. A., & Luckenbaugh, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.019 · Cited by 255
“By eliminating this delay in therapeutic action, it is anticipated that such compounds, when introduced into the clinic, will dramatically reduce the disruption to personal, family, and social life typical of mood disorders as well as the risk of suicidal behavior (6).”
Self-citationGlutamatergic Modulators: The Future of Treating Mood Disorders?
Zarate, C., Machado-Vieira, R., Henter, I., Ibrahim, L., Diazgranados, N., & Salvadore, G. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673229.2010.511059 · Cited by 228
Self-citationMathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220
“This next generation of treatments needs to be more effective, rapid acting and better tolerated than currently available medications.([18]) In this context, considerable research suggests that the glutamatergic system may provide key insights into the pathophysiology of MDD, and in the development of novel therapeuti…”
BackgroundSelf-citationIbrahim, L., DiazGranados, N., Jolkovsky, L., Brutsche, N., Luckenbaugh, D. A., Herring, W. J., Potter, W. Z., & Zarate, C. A. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d70d6 · Cited by 220
“This period of latency is associated with impairments in personal and family life and suicidal behavior.(2,3) Thus, a critical need exists to develop therapies for MDD that act more rapidly than currently available ones.”
BackgroundSelf-citationCooper, M. C., Kilvert, H. S., Hodgkins, P., Roskell, N. S., & Eldar-Lissai, A. (2019) · CNS Drugs · doi:10.1007/s40263-019-00672-w · Cited by 192
Pharmacogenetics of antidepressant response
Porcelli, S., Drago, A., Fabbri, C., Gibiino, S., Calati, R., & Serretti, A. (2011) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.100059 · Cited by 177
“The glutamate system appears to have a crucial role in both acute antidepressant response and maintenance of response.(425)”
BackgroundMachado-Vieira, R., Manji, H. K., & Zarate, C. A. (2009) · The Neuroscientist · doi:10.1177/1073858409336093 · Cited by 171
Self-citationNiciu, M. J., Henter, I. D., Luckenbaugh, D. A., Zarate, C. A., & Charney, D. S. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135950 · Cited by 161
“Due to the widespread treatment resistance to standard antidepressants and mood stabilizers in individuals with mood disorders, as well as the slow onset of action of these agents, there is a critical need for rapid-acting antidepressants with alternative mechanisms of action (5).”
BackgroundSelf-citationClinically Significant Drug Interactions with Newer Antidepressants
Spina, E., Trifirò, G., & Caraci, F. (2012) · CNS Drugs · doi:10.2165/11594710-000000000-00000 · Cited by 160
New targets for rapid antidepressant action
Machado‐Vieira, R., Henter, I. D., & Zarate, C. A. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.001 · Cited by 175
Self-citationMachado-Vieira, R., Yuan, P., Brutsche, N., DiazGranados, N., Luckenbaugh, D., Manji, H. K., & Zarate, C. A. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04659 · Cited by 155
Self-citationThe role of glutamate on the action of antidepressants
Hashimoto, K. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.013 · Cited by 170
“Therefore, the potential misuse and abuse of therapeutically relevant drugs such as ketamine should be carefully considered by psychiatrists, since previous reports of misuse of agents such as benzodiazepines, anti-cholinergic drugs, and stimulants were common (Machado-Vieira et al., 2008).”
BackgroundInfluentialNovel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · CNS Drugs · doi:10.1007/s40263-021-00816-x · Cited by 142
“In addition, these compounds often take weeks or months to reach full effectiveness, underscoring the critical need to develop more effective and rapid-acting interventions for MDD [3].”
BackgroundSelf-citationElectrospun Hydrophilic Janus Nanocomposites for the Rapid Onset of Therapeutic Action of Helicid
Wang, K., Liu, X., Chen, X.-H., Yu, D., Yang, Y., & Liu, P. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b17663 · Cited by 145
Depressive disorders: treatment failures and poor prognosis over the last 50 years
Blackburn, T. P. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.472 · Cited by 136
Caddy, C., Giaroli, G., White, T. P., Shergill, S. S., & Tracy, D. K. (2013) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125313507739 · Cited by 156
O’Connor, R. M., Dinan, T. G., & Cryan, J. F. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.162 · Cited by 144
Lyoo, I. K., Yoon, S., Kim, T.-S., Hwang, J., Kim, J. E., Won, W., Bae, S., & Renshaw, P. F. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010009 · Cited by 123
“However, more than a few weeks may be required to achieve reliable antidepressant responses (1, 2).”
BackgroundChowdhury, G. M. I., Behar, K. L., Cho, W., Thomas, M. A., Rothman, D. L., & Sanacora, G. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.11.006 · Cited by 125
“K etamine has increasingly become a major interest to neuropsychiatric researchers owing to its psychotomimetic effects and rapid onset of antidepressant activity (see [1,2] for recent eviews).”
Mood-stabilizing drugs: mechanisms of action
Schloesser, R. J., Martinowich, K., & Manji, H. K. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.009 · Cited by 136
Self-citationPsychological aspects of infertility. A systematic review
Szkodziak, F., Krzyżanowski, J., & Szkodziak, P. R. (2020) · Journal of International Medical Research · doi:10.1177/0300060520932403 · Cited by 138
“Often weeks or even months are needed to obtain a response to antidepressant treatment.(10) In addition, adverse effects such as withdrawal syndrome, sexual problems, weight gain, and addiction are common.”
BackgroundZeinoddini, A., Sorayani, M., Hassanzadeh, E., Arbabi, M., Farokhnia, M., Salimi, S., Ghaleiha, A., & Akhondzadeh, S. (2015) · Depression and Anxiety · doi:10.1002/da.22340 · Cited by 114
“The delayed antidepressant effect is associated with significant morbidity and increased suicidal risk.[7, 8] Therefore, finding therapeutic strategies with rapid onset and more pronounced effect would have considerable impact on public health.”
BackgroundA review of current evidence for acetyl-l-carnitine in the treatment of depression
Wang, S.-M., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.02.005 · Cited by 110
“Moreover, studies suggest that these neurotransmitters are immediately affected by diverse antidepressants, but clinical improvements are not evident until few weeks later (Machado-Vieira et al., 2008).”
BackgroundWeisler, R. H., Joyce, J. M., McGill, L., Lazarus, A. L., Szamosi, J., Eriksson, H., & Moonstone Study Group (2009) · CNS Spectrums · doi:10.1017/s1092852900020307 · Cited by 123
“1) days for placebo; median(range): 26 (1-56) and 17 (1-56), respectively.”
Betzer, O., Shwartz, A., Motiei, M., Kazimirsky, G., Gispan, I. H., Damti, E., Brodie, C., Yadid, G., & Popovtzer, R. (2014) · ACS Nano · doi:10.1021/nn503131h · Cited by 110
Light therapy in the treatment of patients with bipolar depression: A meta-analytic study
Tseng, P.-T., Chen, Y.-W., Tu, K.-Y., Chung, W., Wang, H.-Y., Wu, C.-K., & Lin, P.-Y. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.001 · Cited by 100
“However, the response to traditional treatment for BD-D is slow, at an average of 2 to 8 weeks (Jick et al., 2004; Machado-Vieira et al., 2008; Walsh et al., 2002).”
BackgroundYoosefi, A., Sepehri, A. S., Kargar, M., Akhondzadeh, S., Sadeghi, M., Rafei, A., Alimadadi, A., & Ghaeli, P. (2013) · Journal of Ect · doi:10.1097/yct.0b013e3182a4b4c6 · Cited by 105
Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Hovelsø, N., Sotty, F., Montezinho, L. P., Pinheiro, P. S., Herrik, K. F., & Mørk, A. (2012) · Current Neuropharmacology · doi:10.2174/157015912799362805 · Cited by 111
Taliaz, D., Spinrad, A., Barzilay, R., Barnett-Itzhaki, Z., Averbuch, D., Teltsh, O., Schurr, R., Darki-Morag, S., & Lerer, B. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01488-3 · Cited by 93
“…at multiple time points be a shortcoming, considering that it was repeatedly shown that trajectories of antidepressant response are commonly not linear [52 – 56], with some studies stating that early therapeutic effects may be better predictors of a subsequent positive long-term outcome [55 – 57].”
Novel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92
“…therapeutic options for these devastating disorders are still far from adequate for treating acute illness episodes, relapses, and recurrences, as well as for restoring premorbid functioning (Insel and Scolnick, 2006,Machado-Vieira et al., 2008), and the development of new therapies is essential.”
BackgroundSelf-citationGlutamatergic Modulators in Depression
Henter, I. D., SOUSA, R. T. D., & Zarate, C. A. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000183 · Cited by 109
Self-citationMoaddel, R., Luckenbaugh, D. A., Xie, Y., Villaseñor, A., Brutsche, N. E., Machado-Vieira, R., Ramamoorthy, A., Lorenzo, M. P., Garcia, A., Bernier, M., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3669-0 · Cited by 86
“…substantial number of patients with major depressive disorder (MDD) and bipolar depression (BD) do not respond to current antidepressant therapy and, for those who do respond, full antidepressant effects typically take 6 weeks or more (Machado-Vieira et al. 2008).”
BackgroundSelf-citationPérez‐Ruixo, C., Rossenu, S., Zannikos, P., Nandy, P., Singh, J. B., Drevets, W. C., & Ruixo, J. J. P. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00953-4 · Cited by 97
Guo, M., Lu, Y., Garza, J. C., Li, Y., Chua, S. C., Zhang, W., Lu, B., & Lu, X.-Y. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.9 · Cited by 92
“In consistence with normal body weight and adiposity, plasma levels of leptin and insulin were indistinguishable between the two genotypes (t(8)1⁄4 1.”
BackgroundSolmi, M., Miola, A., Croatto, G., Pigato, G., Favaro, A., Fornaro, M., Berk, M., Smith, L., Quevedo, J., Maes, M. H. J., et al. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-0935 · Cited by 119
Animal models to improve our understanding and treatment of suicidal behavior
Gould, T. D., Georgiou, P., Brenner, L. A., Brundin, L., Can, A., Courtet, P., Donaldson, Z. R., Dwivedi, Y., Guillaume, S., Gottesman, I. I., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.50 · Cited by 91
“424, [429] [430] [431] Moreover, it has been demonstrated that ketamine might have anti-aggressive properties depending on the experimental model used, 432 which requires further investigation.”
BackgroundSelf-citationRapid-acting antidepressant strategies: mechanisms of action
Bunney, B. G., & Bunney, W. E. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000927 · Cited by 79
“Despite the introduction of new classes of drugs, currently available antidepressants are associated with frequent relapses, low remission rates, multiple side-effects and delayed responses that require 2–10 wk for full clinical efficacy (Gelenberg & Chesen, 2000 ; Insel & Scolnick, 2006 ; Machado-Vieira et al. 2008).”
BackgroundYoon, S. J., Lyoo, I. K., Haws, C. A., Kim, T. S., Cohen, B. M., & Renshaw, P. F. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.2 · Cited by 79
Medeiros, G. C., Gould, T. D., Prueitt, W. L., Nanavati, J., Grunebaum, M. F., Farber, N. B., Singh, B., Selvaraj, S., Machado-Vieira, R., Achtyes, E. D., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01652-1 · Cited by 75
Self-citationBauer, M., Dell’Osso, L., Kasper, S. F., Pitchot, W., Vansvik, E. D., Köhler, J., Jørgensen, L., & Montgomery, S. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.05.079 · Cited by 73
“As AD therapy typically displays slow symptom improvement, often between 2 and 4weeks (Machado-Vieira et al., 2008), the reduced costs associated with decreased hospitalisation and a return to productivity represent benefits of a more rapidly acting therapy (Crown et al., 2002; Montgomery et al.,…”
BackgroundInfluentialTherapeutic Potential of 5-HT2CReceptor Ligands
Hovelsø, N., Cremers, T. I. F. H., & Sotty, F. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.180 · Cited by 73
“The introduction of selective 5-HT reuptake inhibitors (SSRIs) and combined 5-HT and noradrenaline reuptake inhibitors into clinical practice has led to an improvement in the treatment of major depression and anxiety disorders by producing therapeutic benefit without the serious side effects associated with the older…”
BackgroundAccelerating response to antidepressant treatment in depression: A review and clinical suggestions
Nakajima, S., Suzuki, T., Watanabe, K., Kashima, H., & Uchida, H. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.12.001 · Cited by 74
Villaseñor, A., Ramamoorthy, A., Silva dos Santos, M., Lorenzo, M. P., Laje, G., Zarate, C., Barbas, C., & Wainer, I. W. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12494 · Cited by 71
“These drugs are associated with a considerable lag in the onset of antidepressant action, high inter-individual variability in response and many ‘treatmentresistant’ patients (Machado-Vieira et al., 2008).”
BackgroundInfluentialSelf-citationHofstetter, R. K., Fassauer, G. M., & Link, A. (2018) · Journal of Chromatography B · doi:10.1016/j.jchromb.2018.01.024 · Cited by 77
Abbasi, S. H., Mohammadinejad, P., Shahmansouri, N., Salehiomran, A., Beglar, A. A., Zeinoddini, A., Forghani, S., & Akhondzadeh, S. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.04.049 · Cited by 70
Wang, W., Yang, L., Xue, Z., Li, C., Wang, C.-N., Zhao, X., Zhang, J., Wei, X., Chen, X., Cui, W., et al. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.11.025 · Cited by 73
“However, studies suggest that these neurotransmitters are immediately affected by diverse antidepressants, but clinical improvements are not evident until few weeks later (Machado-Vieira et al., 2008).”
Pandey, D. K., Mahesh, R., kumar, A. A., Rao, V. S., Muralidharan, A., & Rajkumar, R. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.09.018 · Cited by 68
New Therapeutic Targets for Mood Disorders
Machado‐Vieira, R., Salvadore, G., Diazgranados, N., Ibrahim, L. A., Latov, D. R., Wheeler‐Castillo, C., Baumann, J., Henter, I. D., & Zarate, C. A. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.65 · Cited by 75
“Novel treatments are expected to address these clinical challenges, and it is critical to the health of our patients that the next generation of treatments for mood disorders be more effective, better tolerated, and act faster than currently available treatments[7].”
Self-citationPerroud, N. A., Bondolfi, G., Uher, R., Gex‐Fabry, M., Aubry, J., Bertschy, G., Malafosse, A., & Kosel, M. (2011) · Pharmacogenomics · doi:10.2217/pgs.10.189 · Cited by 64
Hou, X.-Y., Hu, Z., Zhang, D.-Z., Lu, W., Zhou, J., Wu, P.-F., Guan, X., Han, Q.-Q., Deng, S., Zhang, H., et al. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6737 · Cited by 54
“Optimal therapeutic effectiveness is not achieved because most traditional antidepressants such as selective serotonin reuptake inhibitors (SSRIs) present a delayed onset of their mood-elevating effects and the therapeutic latency of these agents raises the risk of patient committing suicide (28).”
Sikkens, D., Riemersma - Van der Lek, R. F., Meesters, Y., Schoevers, R. A., & Haarman, B. C. M. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.12.117 · Cited by 48
Mechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders
Ghasemi, M., Phillips, C., Fahimi, A., McNerney, M. W., & Salehi, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.07.002 · Cited by 58
“Notably, much of this evidence suggests that rapid antidepressant effects are achievable in humans (Machado-Vieira et al., 2008).”
Wang, Y., Zhang, N., Liu, L., Jiang, H., Hu, D., Wang, Z., Chen, N., & Zhang, Y. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.01.024 · Cited by 52
Güleç, M., Selvı, Y., Boysan, M., Aydın, A., Beşiroğlu, L., & Ağargün, M. Y. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.05.056 · Cited by 45
“All rights reserved. wide and often associated with a negative impact on medical health, quality of life, and productivity (Machado-Vieira et al., 2008).”
SOUSA, R. T. D., Loch, A. A., Carvalho, A. F., Brunoni, A. R., Haddad, M. R., Henter, I. D., Zarate, C. A., & Machado‐Vieira, R. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.149 · Cited by 52
Self-citationChen, Y., Wang, C., & Xu, J. (2019) · Pharmaceutical Biology · doi:10.1080/13880209.2019.1598445 · Cited by 50
“…monoaminergic systems is also deemed as the main target of pharmacological treatments for depression in the last decades, but available antidepressants require 3–8 weeks to produce a therapeutic response though the monoamine neurotransmitters are immediately affected (Machado-Vieira et al. 2008).”
BackgroundPharmacogenetics of Antidepressant Drugs: Current Clinical Practice and Future Directions
Narasimhan, S., & Lohoff, F. W. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.1 · Cited by 51
de Bartolomeis, A., Buonaguro, E. F., Iasevoli, F., & Tomasetti, C. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114523864 · Cited by 51
“Therapeutic options for BD are still far from adequately treating acute episodes, preventing relapses, and reducing recurrences, as well as restoring premorbid functioning (Insel and Scolnick, 2006; Machado-Vieira et al., 2008).”
BackgroundCurcumin as a putative antidepressant
Seo, H., Wang, S., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1008457 · Cited by 42
“Moreover, studies suggest that although neurotransmitters are affected immediately by diverse antidepressants, clinical improvements are not evident until weeks later [3].”
BackgroundKatz, M. M., Bowden, C. L., & Frazer, A. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.08.011 · Cited by 45
“This evidence has inspired investigators to seek agents that are even more rapid in their actions including ones that show changes in mood occurring rapidly, e.g., within hours (Zarate et al., 2006; Machado-Vieira et al., 2008).”
BackgroundEfficacy of Ketamine in Bipolar Depression: Systematic Review and Meta-analysis Retracted
Parsaik, A. K., Singh, B., Khosh-Chashm, D., & Mascarenhas, S. S. (2015) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000106 · Cited by 45
RetractedFassauer, G. M., Hofstetter, R. K., Hasan, M., Oswald, S., Modeß, C., Siegmund, W., & Link, A. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.09.007 · Cited by 46
Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives
Shin, C., & Kim, Y. (2020) · Psychiatry Investigation · doi:10.30773/pi.2019.0236 · Cited by 49
Fagiolini, A. M., Albert, U., Ferrando, L., Herman, E., Muntean, C., Pálová, E., Cattaneo, A., Comandini, A., Dato, G. D., Loreto, G. D., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000304 · Cited by 40
“Indeed, antidepressants that lead to a rapid improvement of depressive symptoms within a few days, and whose effects are sustained in time, would have an important impact on public health and on the life of MDD patients (Machado-Vieira et al., 2008).”
BackgroundUse of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses
Lima, T. D. M., Visacri, M. B., & Aguiar, P. M. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03216-8 · Cited by 50
Tracking the impact of translational research in psychiatry: state of the art and perspectives
Machado‐Vieira, R. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-175 · Cited by 37
“New targets beyond monoamines have been associated with rapid onset of therapeutic actions and improvement in treatment-resistant cases [20].”
BackgroundSelf-citationBenefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression
Katz, E. G., Hough, D. W., Doherty, T., Lane, R., Singh, J. B., & Levitan, B. S. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2024 · Cited by 43
Wang, S., Zhang, Z., Yao, L., Ding, N., Jiang, L., & Wu, Y. (2020) · PLOS ONE · doi:10.1371/journal.pone.0232798 · Cited by 35
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression
Ramaekers, J. G., Reckweg, J. T., & Mason, N. L. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230890 · Cited by 37
Rapid antidepressant effects: moving right along
Martinowich, K., Jimenez, D. V., Zarate, C. A., & Manji, H. K. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.55 · Cited by 38
Self-citationScreening for Neuroprotective and Rapid Antidepressant-like Effects of 20 Essential Oils
Tran, K. N., Nguyen, N. P. K., Nguyen, L. T. H., Shin, H., & Yang, I. (2023) · Biomedicines · doi:10.3390/biomedicines11051248 · Cited by 35
Micheli, L., Spitoni, S., Mannelli, L. D. C., Bilia, A. R., Ghelardini, C., & Pallanti, S. (2020) · Phytotherapy Research · doi:10.1002/ptr.6684 · Cited by 35
Ganea, K., Menke, A., Schmidt, M. V., Lucae, S., Rammes, G., Liebl, C., Harbich, D., Sterlemann, V., Storch, C., Uhr, M., et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.104 · Cited by 31
Modeling the Dynamics of Disease States in Depression
Demic, S., & Cheng, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110358 · Cited by 39
“extracellular level of the monoamines, the onset of an appreciable clinical effect usually takes at least 3–4 weeks [24–29].”
BackgroundGoikolea, J. M., Colom, F., Capapey, J., Torres, I., Valentí, M., Grande, I., Undurraga, J. P., & Vieta, E. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.05.017 · Cited by 33
“In fact, there is much more literature regarding this issue in the treatment of depression (Machado-Vieira et al., 2008).”
BackgroundAssociation between depression subtypes and response to repeated‐dose intravenous ketamine
Wang, C., Zhou, Y., Zheng, W., Liu, W., Zhan, Y., Li, H., Chen, L., Zhang, B., Walter, M., Li, M., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13096 · Cited by 35
“Although antidepressants that act via monoaminergic pathways have dominated in the treatment of depression, a major limitation of all existing antidepressants is the delayed onset of action (1).”
BackgroundRosas-Sánchez, G. U., Germán-Ponciano, L. J., Guillén-Ruiz, G., Cueto‐Escobedo, J., Limón-Vázquez, A. K., Rodríguez‐Landa, J. F., & Soria-Fregozo, C. (2024) · Biomedicines · doi:10.3390/biomedicines12122744 · Cited by 40
Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression
Henter, I. D., SOUSA, R. T. D., Gold, P. W., Brunoni, A. R., Zarate, C. A., & Machado‐Vieira, R. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1253472 · Cited by 31
“be reviewed in this paper – suggests that rapid antidepressant effects are indeed achievable in humans [5].”
BackgroundSelf-citationRosas-Sánchez, G. U., German-Ponciano, L. J., Guillén-Ruiz, G., Cueto-Escobedo, J., Limón-Vázquez, A. K., Rodríguez-Landa, J. F., & Soria-Fregozo, C. (2024) · doi:10.20944/preprints202410.2591.v1 · Cited by 28
Liu, Y., Hui, F., Mo, Y., Jingfang, G., Hongjing, M., Mingfen, S., Shengdong, W., Yan, Y., & Wenjuan, L. (2015) · 中医杂志:英文版 · doi:10.1016/s0254-6272(15)30132-1 · Cited by 31
Alphs, L. D., Fu, D., Williamson, D., Turkoz, I., Jamieson, C., Revicki, D. A., & Canuso, C. M. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113495 · Cited by 28
“attenuate depressive symptoms are attractive treatment options in the management of MDD in patients at increased risk for suicide (Duman, 2018; Machado-Vieira et al., 2008).”
O’Connor, R. M., & Cryan, J. F. (2013) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32835efc78 · Cited by 28
Rapid treatments for depression: Endocannabinoid system as a therapeutic target
Sharafi, A., Pakkhesal, S., Fakhari, A., Khajehnasiri, N., & Ahmadalipour, A. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104635 · Cited by 30
A Systematic Review on the Efficacy of Intravenous Racemic Ketamine for Bipolar Depression
Joseph, B., Parsaik, A. K., Ahmed, A. T., Erwin, P. J., & Singh, B. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001317 · Cited by 28
“The delayed antidepressant effect can cause considerable morbidity including increasing suicidal risk.(3,4) Treatments for suicidal ideation in bipolar depression are severely limited.”
BackgroundGlo1 inhibitors for neuropsychiatric and anti-epileptic drug development
McMurray, K. M. J., Distler, M. G., Sidhu, P. S., Cook, J. M., Arnold, L. A., Palmer, A. A., & Plant, L. D. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140027 · Cited by 26
Autism in the Son of a Woman with Mitochondrial Myopathy and Dysautonomia: A Case Report.
Lee, J., Narang, P., Enja, M., & Lippmann, S. (2015) · Europe PMC (PubMed Central) · Cited by 24
Potential Pathways Involved in the Rapid Antidepressant Effects of Nitrous Oxide
Zarate, C. A., & Machado‐Vieira, R. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.04.007 · Cited by 24
“In particular, such studies may offer key insights into the mechanism of action of rapid-acting antidepressants as well as the neurobiology of mood disorders (1).”
BackgroundSelf-citation
Metadata
- Authors
- Machado-Vieira, R., Salvadore, G., Luckenbaugh, D. A., Manji, H. K., & Zarate, C. A.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2008-06-15
- Volume
- 69
- Issue
- 6
- Pages
- 946-958
- ISSN
- 0160-6689 (ISSN-L)
- PMC
- PMC2699451
- OpenAlex
- W2000031234
- Cited by
- 195
- References
- 147
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 7 · 2023: 11 · 2022: 8 · 2021: 13 · 2020: 13 · 2019: 9 · 2018: 8 · 2017: 8 · 2016: 7 · 2015: 10 · 2014: 15 · 2013: 13 · 2012: 18
- FWCI
- 8.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Alliance for Research on Schizophrenia and Depression
- National Institutes of Health
- National Institute of Mental Health (Z01MH002853, Z01MH002828, Z01MH002857)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- depression, glutamate, sleep, rapid-acting antidepressants, suicidal behavior, treatment latency
- MeSH terms
- Antidepressive Agents, Major Depressive Disorder, Humans, Severity of Illness Index, Time Factors, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.